Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jameel Hourani"'
Autor:
Horst Schran, Richard Hartman, Sharon Barto, John J. Sramek, Neal R. Cutler, Ravi Anand, Thomas Shiovitz, Jameel Hourani, Tom S. Wardle
Publikováno v:
Clinical Drug Investigation. 17:51-58
Objective: This inpatient, randomised, three-way crossover study evaluated the steady-state pharmacokinetics and tolerability of generic clozapine (Creighton) versus Clozaril® (Novartis brand of clozapine) in patients with schizophrenia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0f6f9884ed3ab7f957a1348ec4b5245
https://doi.org/10.2165/00044011-199917010-00006
https://doi.org/10.2165/00044011-199917010-00006
Autor:
Misser Forrest, Stanford S. Jhee, Helle Mengel, Neal R. Cutler, John J. Sramek, Jameel Hourani
Publikováno v:
Life Sciences. 62:195-202
Lu 25-109 is a functionally selective partial M1 agonist with M2/M3 antagonist properties. This double-blind, placebo-controlled, two-part, inpatient bridging study was designed to evaluate the safety and tolerability of multiple oral doses of Lu 25-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2a14c876c0830bf35d33fcd618764c1
https://doi.org/10.1016/s0024-3205(97)01087-4
https://doi.org/10.1016/s0024-3205(97)01087-4
Autor:
Neal R. Cutler, Stanford S. Jhee, Walid Awni, Jameel Hourani, John J. Sramek, Randall J. Mack, Sharon Barto
Publikováno v:
Journal of Clinical Psychopharmacology. 17:419-422
The novel antipsychotic sertindole has demonstrated efficacy in psychosis with an extrapyramidal syndrome profile indistinguishable from placebo.Prior trials of sertindole have increased the dose by 4 mg every third day, whereas the present study eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f126499211caa15e280634d97790f9
https://doi.org/10.1097/00004714-199710000-00011
https://doi.org/10.1097/00004714-199710000-00011
Autor:
Jameel Hourani, John J. Sramek, Neal R. Cutler, C.M. Jensen, Fresquet A, Stanford S. Jhee, Martinez L, Bolles K, A.T. Carrington, G. Marion-Landais
Publikováno v:
Journal of Clinical Psychopharmacology. 16:454-458
Lesopitron, a 5-hydroxytryptamine 1A agonist, is a new potential anxiolytic of the azapirone class. It has greater potency in animal models of anxiety than buspirone, gepirone, or ipsapirone, and it lacks the antidopaminergic effects associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b8b49f86c237ea2bb20f692b7286b91
https://doi.org/10.1097/00004714-199612000-00009
https://doi.org/10.1097/00004714-199612000-00009
Publikováno v:
Life sciences. 64(14)
Reduced cholinergic transmission is a key neurotransmitter dysfunction in Alzheimer's Disease (AD). NXX-066, a physostigmine analog and acetylcholinesterase (AChE) inhibitor, has demonstrated activity in animal models of memory function, and was well
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f9f7d33678e9ec2d8ca755d5f656ca8
https://pubmed.ncbi.nlm.nih.gov/10210264
https://pubmed.ncbi.nlm.nih.gov/10210264
Autor:
Daniel J. Hurley, John J. Sramek, Julie Satterwhite, Jameel Hourani, Federico Dies, Neal R. Cutler, Thomas S. Wardle
Publikováno v:
Journal of clinical pharmacology. 35(8)
Xanomeline tartrate (active ingredient xanomeline) is a muscarinic agonist that has demonstrated specificity for the M1 receptor in preclinical studies and has been well tolerated at dosages up to 50 mg three times a day in healthy elderly subjects.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa2c6a2b696e5d86c930206f6af3519e
https://pubmed.ncbi.nlm.nih.gov/8522637
https://pubmed.ncbi.nlm.nih.gov/8522637
Autor:
Neal R. Cutler, C. Viereck, John J. Sramek, Thomas S. Wardle, J A Stewart, Jameel Hourani, F.J. Huff
Publikováno v:
Life sciences. 57(12)
Besipirdine hydrochloride is a novel compound with cholinergic and adrenergic activity being investigated as a treatment for Alzheimer's disease (AD). The pharmacodynamics of some anti-dementia drugs are known to differ in patients with AD as compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1f268c04d737e30bec1ac5613c089c9
https://pubmed.ncbi.nlm.nih.gov/7674813
https://pubmed.ncbi.nlm.nih.gov/7674813